SCHEMBL2947235

SCHEMBL2947235

c1ccc(CNCc2ccccn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
CHRM2 P08172 1/20 0.59
MAOA P21397 1/20 0.58
MAOB P27338 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.56
KDM4E B2RXH2 2/20 0.56
POLB P06746 1/20 0.56
CCR5 P51681 1/20 0.54
FABP1 P07148 1/20 0.53
FABP6 P51161 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
KDM4A O75164 1/20 0.53
KDM4B O94953 1/20 0.53
KDM5C P41229 1/20 0.53
KDM5B Q9UGL1 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29860055 0.94 L3MBTL1 (0.62) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL3314110 0.94 L3MBTL1 (0.62) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL29761156 0.92 CHRM2 (0.66) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL29438821 0.89 CHRM2 (0.70) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL230222 0.89 CHRM2 (0.70) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL5892980 0.89 NPC1 (0.55) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL30225577 0.89 KMT2A (0.68) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL14931741 0.89 KMT2A (0.68) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL22305532 0.88 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ACHRM2MAOA
SCHEMBL25211342 0.87 CHRM2 (0.68) ALDH1A1MEN1KMT2ACHRM2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 CN claimed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 CN disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20230210840-A1 BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS NORTHWESTERN UNIVERSITY 2023-07-06 US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
EP-0625507-B1 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO (JP) 1997-07-23 EP disclosed
US-5621010-A ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-04-15 US disclosed
US-5576335-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS NISSHIN FLOUR MILLING CO., LTD. (JP) 1996-11-19 US disclosed
EP-0665216-A1 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1995-08-02 EP disclosed
EP-0625507-A2 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-11-23 EP disclosed
EP-0005014-A1 Clavulanic acid derivatives, preparation and compositions BEECHAM GROUP PLC (GB) 1979-10-31 EP disclosed
US-4112100-A INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4069224-A N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS THE UPJOHN COMPANY (US) 1978-01-17 US disclosed
US-4008326-A INCREASING PRODUCTION OF PROSTAGLANDINS THE UPJOHN COMPANY (US) 1977-02-15 US disclosed
US-4006239-A Benzoic acid amides for mycobacterium infections BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 ALDH1A1 29/4885MEN1 521/4885KMT2A 2276/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 ALDH1A1 3235/4885MEN1 2831/4885KMT2A 2309/4885
US-20230210840-A1 BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS NOS1, NOS2, NOS3 ALDH1A1 2101/4885MEN1 4207/4885KMT2A 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.